10 completed, 3 recruiting, 3 unknown, 2 active not recruiting. 8 Phase 2, 5 Phase 1, 5 Phase 4, 4 Not applicable, 4 Phase 3.
Follow Terazosin: new trials by email Literature Review of Terazosin trials Research Report on Terazosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis Terazosine, Placebo - Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities | Early Phase 1 | Recruiting | University of Iowa | 20 | 2026-08-12 | 2026-09-09 |
| Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD) | Phase 3 | Recruiting | University College, London | 1200 | 2025-09-12 | 2025-10-03 |
| Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms Terazosin, Tamsulosin - Stent Related Symptoms | Phase 3 | Recruiting | Penang Hospital, Malaysia | 150 | 2025-06-01 | 2026-07-24 |
| Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients Terazosin - Parkinson Disease, Gait Analysis | Phase 4 | Unknown | I.R.C.C.S. Fondazione Santa Lucia | 50 | 2023-12-01 | 2023-09-22 |
| Target Engagement of Terazosin in Healthy Adults Terazosin - Healthy | Phase 1 | Active not recruiting | University of Iowa | 18 | 2021-03-26 | 2025-01-14 |
| Terazosin Effect on Cardiac Changes in Early Parkinson's Disease Terazosin - REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease | Phase 2 | Active not recruiting | Cedars-Sinai Medical Center | 15 | 2020-11-01 | 2026-03-02 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| A Pilot Study of Terazosin for Parkinson's Disease Terazosin 5 MG, Placebo oral capsule - Parkinson Disease | Phase 1 / Phase 2 | Completed | Jordan Schultz | 13 | 2019-09-24 | 2022-05-16 |
| Deflox Tablets Bioequivalence (BE) Trial Deflox®, Cataflam DD® - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 16 | 2019-09-21 | 2021-02-24 |
| Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting Terazosin, Carotid artery stenting - Carotid Artery Stenosis | Phase 2 | Unknown | Capital Medical University | 160 | 2018-03-02 | 2018-12-11 |
| Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus amlodipine, hydralazine, terazosin or hydrochlorothiazide - Type 2 Diabetes, Hypertension | Phase 4 | Completed | Tulane University School of Medicine | 28 | 2012-01-01 | 2023-08-21 |
| The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms Placebo, Terazosine, Tolterodine - Disorder of Urinary Stent | Phase 2 / Phase 3 | Completed | Urmia University of Medical Sciences | 104 | 2012-01-01 | 2015-03-02 |
| Diesel Exhaust and Vascular Function Diesel Exhaust, Filtered Air, Terazosin - Cardiovascular Effects | Not applicable | Unknown | University of Washington | 24 | 2012-01-01 | 2015-08-03 |
| Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF Aggressive Blood Pressure control - Atrial Fibrillation | Phase 4 | Completed | Nova Scotia Health Authority | 184 | 2009-12-01 | 2017-06-20 |
| The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia selective alpha 1-blockers, celecoxib, alpha-blocker and NSAID - Benign Prostatic Hyperplasia | Phase 4 | Withdrawn | Samsung Medical Center | 2008-05-01 | 2013-06-10 | |
| Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin terazosin - Hyperhidrosis | Phase 4 | Completed | Thomas Jefferson University | 23 | 2007-03-01 | 2016-08-25 |
Showing 20 of 24. Sign in to see all of them.
Parkinson Disease (5) · Hypertension (4) · Diabetes Mellitus, Type 2 (2) · Prostatic Hyperplasia (2) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Atherosclerosis (1) · Atrial Fibrillation (1) · Cardiovascular Diseases (1) · Carotid Stenosis (1) · Coronary Disease (1) · Depressive Disorder (1) · Diabetes Mellitus (1) · Directly Observed Therapy (1) · Essential Hypertension (1)
Qiang Zhang (2) · Thomas Jefferson University (2) · University of Iowa (2) · Anhui Medical University (1) · Capital Medical University (1) · Cedars-Sinai Medical Center (1) · Ergun Y. Uc (1) · Hospital Authority, Hong Kong (1) · I.R.C.C.S. Fondazione Santa Lucia (1) · Jordan Schultz (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Nandakumar Narayanan (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Nova Scotia Health Authority (1) · Penang Hospital, Malaysia (1)
United States (13) · China (3) · Canada (2) · Iran (1) · Malaysia (1) · Mexico (1) · South Korea (1) · United Kingdom (1)
Jordan Schultz, PharmD (2) · Nandakumar Narayanan, MD, PhD (2) · Rajnish Mago, MD (2) · Adam P Bress, PharmD, MS (1) · Ali Tehranchi, Urologist (1) · Andrea Swenson, MD (1) · Antonella Peppe, MD, PhD (1) · Chi Wai Cheng, Dr (1) · Denise Simons-Morton, MD, PhD (1) · Joel D Kaufman, MD, MPH (1) · Kyu-Sung Lee, Ph.D., M.D. (1) · Michele L Tagliati, MD (1) · Nandakumar Narayanan (1) · Ping Liu, PhD (1)
PMID 23638448, PMID 18539917, PMID 19371934, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23238658, PMID 23412077, PMID 23990163, PMID 24170759, PMID 24296848, PMID 24493100, PMID 24595629, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389, PMID 25666468, PMID 25887355, PMID 26261902, PMID 26459421, PMID 26464212, PMID 26476086, PMID 26822326
N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P50ES015915 (1)